What to Know About New Hypertension Guidelines in CKD What to Know About New Hypertension Guidelines in CKD
Dr Ileana Pi ña asks Dr Peter A. McCullough what physicians need to know about heart failure and kidney disease, and the new hypertension guidelines in chronic kidney disease.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 13, 2021 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Race Coefficient Alters Kidney Disease Stage in Many Black Patients Race Coefficient Alters Kidney Disease Stage in Many Black Patients
Yet another database documents that applying the race coefficient when calculating eGFR in Black adults reclassifies many into a less severe stage of chronic kidney disease. But does this impact outcomes?Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 7, 2021 Category: Consumer Health News Tags: Nephrology News Source Type: news

Ahead of FDA meeting, S.F. biotech's stock dips on questions about data analysis
Ahead of a critical meeting with an FDA committee, FibroGen Inc. stock tumbled more than 30% after hours on a fresh look at data around the safety of the San Francisco company's drug to treat anemia in chronic kidney disease patients. FibroGen officials said they continue to be confident in the risk-benefit profile of its drug, called roxadustat. Investors were not as optimistic: FibroGen stock (NASDAQ: FGEN) fell from a Tuesday high of $35.63 per share to $34.64 — off 2.8% on the day — then… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 6, 2021 Category: Biotechnology Source Type: news

Ahead of FDA meeting, S.F. biotech's stock dips on questions about data analysis
Ahead of a critical meeting with an FDA committee, FibroGen Inc. stock tumbled more than 30% after hours on a fresh look at data around the safety of the San Francisco company's drug to treat anemia in chronic kidney disease patients. FibroGen officials said they continue to be confident in the risk-benefit profile of its drug, called roxadustat. Investors were not as optimistic: FibroGen stock (NASDAQ: FGEN) fell from a Tuesday high of $35.63 per share to $34.64 — off 2.8% on the day — then… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 6, 2021 Category: American Health Source Type: news

Sodium Intake and Progression of Chronic Kidney Disease Sodium Intake and Progression of Chronic Kidney Disease
A new editorial calls for a randomized controlled trial regarding the effects of sodium intake on CKD progression. Would an RCT help bridge the evidence gap?Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 1, 2021 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Cardiac and Kidney Benefits of Empagliflozin in Heart Failure
This study examined the effect of empagliflozin on cardiovascular and kidney outcomes in heart failure patients with or without chronic kidney disease.Circulation (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - March 30, 2021 Category: Transplant Surgery Tags: Cardiology Journal Article Source Type: news

Akebia Submits New Drug Application (NDA) to the FDA for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis
CAMBRIDGE, Mass., March 30, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today announced that it has submitted... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - March 30, 2021 Category: Drugs & Pharmacology Source Type: news

$3 Million NIH grant for Colorado School of Public Health Worker Health study
(University of Colorado Anschutz Medical Campus) Three groups from the Colorado School of Public Health (ColoradoSPH) have been awarded a $3 million 5-year grant from the National Institutes of Health (NIH) to study the effects of air pollution and climate on the kidney health of sugarcane workers in Guatemala. The award provides funding to identify how air pollutants contribute to chronic kidney disease of unknown origin (CKDu), a growing international epidemic. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 25, 2021 Category: International Medicine & Public Health Source Type: news

Phone App Flags Medication Discrepancies in Kidney Disease Phone App Flags Medication Discrepancies in Kidney Disease
A new phone app for patients with chronic kidney disease cut the incidence of medication discrepancies with potentially severe consequences by a relative 60% in a randomized trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 22, 2021 Category: Cardiology Tags: Nephrology News Source Type: news

Digital App Cuts Meds Discrepancies in Outpatients With CKD
FRIDAY, March 19, 2021 -- Use of a digital application, eKidneyCare, can reduce total medication discrepancies and the severity of clinically relevant medication discrepancies among outpatients with advanced chronic kidney disease, according to a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 19, 2021 Category: Pharmaceuticals Source Type: news

Physical Activity Should Be Part of Chronic Kidney Disease Care Physical Activity Should Be Part of Chronic Kidney Disease Care
' Our results suggest that physical activity should be integrated into the clinical care of patients with kidney disease'to reduce risks of death and major adverse cardiorenal events, say researchers.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 15, 2021 Category: Consumer Health News Tags: Nephrology News Source Type: news

2021 KDIGO Guideline Lowers Target Systolic BP for Adults With CKD
MONDAY, March 15, 2021 -- The 2021 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for management of blood pressure in patients with chronic kidney disease (CKD) increase eligibility for blood pressure lowering, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 15, 2021 Category: Pharmaceuticals Source Type: news

You are not a cat, but a cat could someday help treat your chronic kidney disease
(Wake Forest Baptist Medical Center) The Wake Forest Institute for Regenerative Medicine is investigating how cats with chronic kidney disease could someday help inform treatment for humans. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 12, 2021 Category: International Medicine & Public Health Source Type: news

Physical Activity May Improve Cardiorenal Outcomes in CKD
THURSDAY, March 11, 2021 -- For individuals with chronic kidney disease (CKD), physical activity of 7.5 to
Source: Drugs.com - Pharma News - March 11, 2021 Category: Pharmaceuticals Source Type: news

Workouts Boost Health of People With Kidney Disease
THURSDAY, March 11, 2021 -- Do you struggle with chronic kidney disease? Exercise may be the best prescription for your condition, new research out of Taiwan suggests. Scientists found that highly active patients had a lower risk of kidney disease... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 11, 2021 Category: General Medicine Source Type: news

Mayo Clinic Minute: Understanding chronic kidney disease
Chronic kidney disease is the gradual loss of kidney function. Some people, including African Americans, Native Americans and Asian Americans, are at higher risk of developing chronic kidney disease. March 11 is World Kidney Day, and Dr. LaTonya Hickson, a Mayo Clinic nephrologist, says chronic kidney disease shows no early symptoms, so it's important to know [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 11, 2021 Category: Databases & Libraries Source Type: news

Ayurvedic formulations can help rejuvenate ailing kidney cells, say researchers
The conclusion was reached following administration of punarnava-based NEERI KFT herbal formulation that comprises lotus leaves, patharchur and other major herbs to the subjects of chronic kidney disease, according to a study. (Source: The Economic Times)
Source: The Economic Times - March 10, 2021 Category: Consumer Health News Source Type: news

Expert Alert: Risk for chronic kidney disease even more critical due to COVID-19 pandemic
ROCHESTER, Minn. -- An estimated 1 in 10 people worldwide have chronic kidney disease, but most of them don't know it. That lack of awareness is especially concerning because people with chronic kidney disease who are infected with COVID-19 are at higher risk for serious illness. It is important that people understand their risk for [...] (Source: Mayo Clinic Minnesota News)
Source: Mayo Clinic Minnesota News - March 8, 2021 Category: Hospital Management Source Type: news

Think you're eligible for a Covid-19 vaccine? The list keeps growing
With expanded availability for the Covid-19 vaccine, social media and text streams are abuzz with people announcing they got an appointment. But the state still has very specific eligibility restrictions governing who can get a vaccine where. Here's who is eligible: The newest group of eligible includes individuals 16 or older with chronic conditions and co-morbidities (cancer, current or in remission; chronic kidney disease; pulmonar y disease such as COPD or asthma; intellectual and developmental… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - March 5, 2021 Category: Pharmaceuticals Authors: Tracey Drury Source Type: news

Managing Hyperuricemia and Gout in Chronic Kidney Disease Managing Hyperuricemia and Gout in Chronic Kidney Disease
How are hyperuricemia and gout best managed in patients with chronic kidney disease?Current Opinion in Nephrology and Hypertension (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 2, 2021 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

SOX9 is required for kidney fibrosis and activates NAV3 to drive renal myofibroblast function
Renal fibrosis is a common end point for kidney injury and many chronic kidney diseases. Fibrogenesis depends on the sustained activation of myofibroblasts, which deposit the extracellular matrix that causes progressive scarring and organ failure. Here, we showed that the transcription factor SOX9 was associated with kidney fibrosis in humans and required for experimentally induced kidney fibrosis in mice. From genome-wide analysis, we identified Neuron navigator 3 (NAV3) as acting downstream of SOX9 in kidney fibrosis. NAV3 increased in abundance and colocalized with SOX9 after renal injury in mice, and both SOX9 and NAV3...
Source: Signal Transduction Knowledge Environment - March 2, 2021 Category: Science Authors: Raza, S., Jokl, E., Pritchett, J., Martin, K., Su, K., Simpson, K., Birchall, L., Mullan, A. F., Athwal, V. S., Doherty, D. T., Zeef, L., Henderson, N. C., Kalra, P. A., Hanley, N. A., Piper Hanley, K. Tags: STKE Research Articles Source Type: news

New blood pressure-lowering guidelines could benefit 25 million americans with chronic kidney disease
(Johns Hopkins University Bloomberg School of Public Health) A recommendation for more intensive blood pressure management from an influential global nonprofit that publishes clinical practice guidelines in kidney disease could, if followed, benefit nearly 25 million Americans. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 23, 2021 Category: International Medicine & Public Health Source Type: news

Association of baclofen with falls and fractures in patients with CKD - Muanda FT, Blake PG, Weir MA, Bathini L, Chauvin K, Dixon SN, McArthur E, Sontrop JM, Moist L, Kim RB, Garg AX.
Baclofen is a popular muscle relaxant that is eliminated primarily unchanged in the urine. We recently reported a higher risk of encephalopathy in a cohort of 15,942 older adults with chronic kidney disease (CKD) who started baclofen at ≥20 mg/day vs. ... (Source: SafetyLit)
Source: SafetyLit - February 15, 2021 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

International Women's Day Panel on diversity in health evidence synthesis - 8 March 2021
International Women's Day is March 8th!  Join us as we discuss and highlight minority women and young investigators working in health science and evidence synthesis. Hear about their career paths, who has inspired them, and what advice they have for other women interested in or working in health evidence synthesis.  Learn about Cochrane’s role in evidence Synthesis and how anyone can get involved.Each year Cochrane hosts an event in the name of Anne Anderson, a pioneering woman in health evidence synthesis.   In the past it's been the'Ann Anderson Walk'at the Cochrane Colloquium to raise money for...
Source: Cochrane News and Events - February 9, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news

International Women's Day Panel on diversity in health evidence synthesis
On International Women's Day 2021 we discussed and highlighted minority women and young investigators working in health science and evidence synthesis.  Watch the recording to hear about their career paths, who has inspired them, and what advice they have for other women interested in or working in health evidence synthesis.  Learn about Cochrane’s role in evidence Synthesis and how anyone can get involved.Each year Cochrane hosts an event in the name of Anne Anderson, a pioneering woman in health evidence synthesis.   In the past it's been the'Anne Anderson Walk'at the Cochrane Colloquium to rais...
Source: Cochrane News and Events - February 9, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news

VIDEO: International Women's Day Panel on diversity in health evidence synthesis
On International Women's Day 2021 we discussed and highlighted minority women and young investigators working in health science and evidence synthesis.  Watch the recording to hear about their career paths, who has inspired them, and what advice they have for other women interested in or working in health evidence synthesis.  Learn about Cochrane’s role in evidence Synthesis and how anyone can get involved.Each year Cochrane hosts an event in the name of Anne Anderson, a pioneering woman in health evidence synthesis.   In the past it's been the'Anne Anderson Walk'at the Cochrane Colloquium to rais...
Source: Cochrane News and Events - February 9, 2021 Category: Information Technology Authors: Muriah Umoquit Source Type: news

Bayer-submits-finerenone-marketing-authorization-China-treatment-chronic-kidney-disease-2-diabetes
(Source: Bayer Company News)
Source: Bayer Company News - February 9, 2021 Category: Pharmaceuticals Source Type: news

AstraZeneca's Dapagliflozin tablets get DCGI nod for patients with chronic kidney disease
The company has "received Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the DCGI for Dapagliflozin tablets 10 mg," AstraZeneca Pharma India said in a filing to BSE. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - February 6, 2021 Category: Pharmaceuticals Source Type: news

Many Cancer Survivors Have Conditions Linked to Risk for Severe COVID-19 Illness
WEDNESDAY, Feb. 3, 2021 -- More than half of cancer survivors have underlying medical conditions associated with severe COVID-19 illness, including chronic obstructive pulmonary disease, heart diseases, diabetes, chronic kidney disease, and obesity,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 3, 2021 Category: Pharmaceuticals Source Type: news

Lupin gets USFDA nod to market generic Sevelamer Carbonate tablets
The product is indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis, Lupin said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 25, 2021 Category: Pharmaceuticals Source Type: news

Stopping RAS Inhibitors May Worsen Outcomes in CKD
FRIDAY, Jan. 15, 2021 -- The decision to stop renin-angiotensin system (RAS) inhibitor therapy in patients with advanced chronic kidney disease (CKD) should take into account both cardiovascular risk and the risk for kidney replacement therapy,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 15, 2021 Category: Pharmaceuticals Source Type: news

Stopping Common Heart Meds Could Be Risky for Kidney Patients
THURSDAY, Jan. 14, 2021 -- Patients with chronic kidney disease who stop using a class of common blood pressure medications may lower their risk for dialysis, but they also raise their odds of cardiovascular disease, a new study finds. The blood... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 14, 2021 Category: General Medicine Source Type: news

Metformin use reduces risk of death for patients with COVID-19 and diabetes
(University of Alabama at Birmingham) Use of the diabetes drug metformin -- before a diagnosis of COVID-19 -- is associated with a threefold decrease in mortality in COVID-19 patients with Type 2 diabetes, according to a racially diverse study at the University of Alabama at Birmingham. Diabetes is a significant comorbidity for COVID-19. This beneficial effect remained, even after correcting for age, sex, race, obesity, and hypertension or chronic kidney disease and heart failure. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - January 14, 2021 Category: Infectious Diseases Source Type: news

US-FDA-grants-priority-review-New-Drug-Application-finerenone-treat-patients-chronic-kidney-disease
(Source: Bayer Company News)
Source: Bayer Company News - January 12, 2021 Category: Pharmaceuticals Source Type: news

First-degree relative with kidney disease increases disease risk by three-fold
(National Kidney Foundation) In a large population-based family study, family history of kidney disease was strongly associated with increased risk of chronic kidney disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 12, 2021 Category: International Medicine & Public Health Source Type: news

Updated advice on COVID-19 vaccination in pregnancy and women who are breastfeeding, RCOG
The Government has today accepted the recommendation from the Medicines and Healthcare products Regulatory Agency (MHRA) to authorise Oxford University/AstraZeneca's COVID-19 vaccine for use. The Joint Committee on Vaccination and Immunisation (JCVI) has also published its latest advice for the priority groups to receive the Oxford University/AstraZeneca and the Pfizer/BioNTech vaccines. This includes updated advice for pregnant and breastfeeding women who meet other criteria for priority vaccination. The JCVI confirms that although the available data do not indicate any safety concern or harm to pregnancy, there is insuf...
Source: Current Awareness Service for Health (CASH) - December 31, 2020 Category: Consumer Health News Source Type: news

Stopping RAS inhibitors tied to worse outcomes in patients with chronic kidney disease
(Karolinska Institutet) Small studies have suggested that a group of medications called RAS inhibitors may be harmful in persons with advanced chronic kidney disease, and physicians therefore often stop the treatment in such patients. Researchers at Karolinska Institutet now show that although stopping the treatment is linked to a lower risk of requiring dialysis, it is also linked to a higher risk of cardiovascular events and death. The results are published inThe Journal of the American Society of Nephrology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 29, 2020 Category: International Medicine & Public Health Source Type: news

Fine Particulate Matter Linked to Increased Prevalence of CKD
WEDNESDAY, Dec. 23, 2020 -- Fine particulate matter (PM2.5) is associated with an increased prevalence of chronic kidney disease (CKD) and albuminuria in the general population in China, according to a study published online Dec. 17 in the Journal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 23, 2020 Category: Pharmaceuticals Source Type: news

After nearly $1 billion and 27 years, S.F. biotech now must wait another 90 days for 1st FDA decision
A Food and Drug Administration decision on whether to approve a drug from FibroGen Inc. to treat anemia in chronic kidney disease patients was delayed Friday for 90 days. San Francisco-based FibroGen (NASDAQ: FGEN) and partner AstraZeneca plc (NASDAQ: AZN) expected a decision by Sunday, but the FDA said it required additional analyses of existing clinical trial results for the drug, called roxadustat. The agency moved the decision date to March 20. FibroGen CEO En rique Conterno said in a statement… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 21, 2020 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

Air Pollution Takes a Toll on Your Kidneys
THURSDAY, Dec. 17, 2020 -- Tiny particles of air pollution were already known to raise people's risk of developing heart and lung disease, but a new study suggests they might also raise the risk of developing chronic kidney disease. Researchers from... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 17, 2020 Category: General Medicine Source Type: news

FGF23, frailty, and falls in SPRINT - Jovanovich A, Ginsberg C, You Z, Katz R, Ambrosius WT, Berlowitz D, Cheung AK, Cho M, Lee AK, Punzi H, Rehman S, Roumie C, Supiano MA, Wright CB, Shlipak M, Ix JH, Chonchol M.
BACKGROUND/OBJECTIVES: Chronic kidney disease (CKD) is associated with frailty. Fibroblast growth factor 23 (FGF23) is elevated in CKD and associated with frailty among non-CKD older adults and individuals with human immunodeficiency virus. Whether FGF23 i... (Source: SafetyLit)
Source: SafetyLit - December 10, 2020 Category: International Medicine & Public Health Tags: Age: Elder Adults Source Type: news

Kidney disease leading risk factor for COVID-related hospitalization
(Geisinger Health System) An analysis of Geisinger's electronic health records has revealed chronic kidney disease to be the leading risk factor for hospitalization from COVID-19. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 2, 2020 Category: Infectious Diseases Source Type: news

Weighing in on chronic kidney disease
(Source: ScienceNOW)
Source: ScienceNOW - November 26, 2020 Category: Science Authors: Nusinovich, Y. Tags: twil Source Type: news

AHA: Sotagliflozin Beneficial for T2DM With Heart Failure
WEDNESDAY, Nov. 25, 2020 -- Sotagliflozin is beneficial for the treatment of type 2 diabetes in patients with recent worsening heart failure as well as in patients with chronic kidney disease, according to two studies published online Nov. 16 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 25, 2020 Category: Pharmaceuticals Source Type: news

Finerenone's Heart Benefits Hold in T2D Without CVD: FIDELIO-DKD Finerenone's Heart Benefits Hold in T2D Without CVD: FIDELIO-DKD
The nonsteroidal mineralocorticoid receptor antagonist showed cardiovascular benefits in patients with type 2 diabetes and chronic kidney disease, with or without CVD, a phase 3 trial shows.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 24, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Non-invasive electrolyte levels' measuring method can prevent sudden cardiac death
(Kaunas University of Technology) Researchers from Kaunas University of Technology (KTU), Lithuania came up with the idea on how to measure fluctuating blood potassium levels non-invasively, through electrocardiogram. The researchers claim that their method may become a digital biomarker in the future for managing electrolyte levels. This would be a huge step towards preventing potentially life-threatening conditions among people who suffer from chronic kidney disease. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - November 23, 2020 Category: Biology Source Type: news

FDA Authorizes Emergency Use Of Regeneron ’ s COVID Treatment Taken By President Trump
(CNN) — The US Food and Drug Administration on Saturday issued an emergency use authorization for Regeneron’s antibody cocktail to treat Covid-19 in high-risk patients with mild to moderate disease. President Donald Trump received the therapy, called REGEN-COV2, when he was hospitalized for coronavirus. The treatment has to be infused into the bloodstream and is meant to mimic an immune response to infection. The cocktail reduced Covid-19-related hospitalizations and emergency room visits in some patients within 28 days of treatment, the FDA said in a news release. Regeneron’s chief ex...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 22, 2020 Category: Consumer Health News Authors: CBS Boston Tags: Boston News Covid-19 Boston, MA Health Syndicated CBSN Boston CNN Coronavirus President Trump Coronavirus Regeneron Source Type: news

Bristol secures £ 45M to advance gene therapy treatment of chronic kidney diseases
The University of Bristol has secured a £ 45million deal to advance its groundbreaking gene therapy technology for chronic kidney diseases. The commitment, made by healthcare company Syncona Ltd to Bristol spin-out Purespring Therapeutics, aims to address a global unmet need for renal conditions in one of the largest single investments made to a new UK university biotech company. (Source: University of Bristol news)
Source: University of Bristol news - November 19, 2020 Category: Universities & Medical Training Tags: Health, Research; Faculty of Life Sciences, Faculty of Health Sciences, Faculty of Health Sciences, Bristol Medical School; Press Release Source Type: news

17.11.20: Not intended for U.S. and UK Media - Late-Breaking Data from subgroup analysis of Phase III FIDELIO-DKD study presented at the American Heart Association (AHA) Scientific Sessions 2020
Finerenone showed consistent benefits on cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes with or without history of cardiovascular diseaseIn the FIDELIO-DKD Phase III study among patients with chronic kidney disease and type 2 diabetes, overall finerenone significantly lowered the combined risk of cardiovascular events, with comparable treatment efficacy for patients with or without history of cardiovascular disease / People with chronic kidney disease and type 2 diabetes are three times more likely to die from a cardiovascular-related cause than those with type 2 diabetes alone / Finere...
Source: Bayer IR Newsfeed: Events - November 17, 2020 Category: Pharmaceuticals Source Type: news

New medication helps heart health in people with chronic kidney disease, Type 2 diabetes
(American Heart Association) Results of a large, international clinical trial on the novel medication finerenone indicate it reduced the rate of death, heart attack, stroke and hospitalization for heart failure among patients with chronic kidney disease and Type 2 diabetes. Finerenone helped patients with chronic conditions improve their heart health, regardless of if they had a history of cardiovascular disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 17, 2020 Category: International Medicine & Public Health Source Type: news